| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
|
2
|
Development of the proteasome inhibitor Velcade (Bortezomib).
|
Cancer Invest
|
2004
|
3.40
|
|
3
|
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
|
Blood
|
2012
|
2.65
|
|
4
|
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
|
Blood
|
2012
|
2.27
|
|
5
|
CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.
|
J Urol
|
2012
|
2.05
|
|
6
|
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
|
Br J Haematol
|
2013
|
1.68
|
|
7
|
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
|
J Med Chem
|
2006
|
1.58
|
|
8
|
Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
|
Blood
|
2013
|
1.52
|
|
9
|
Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
|
Exp Hematol
|
2012
|
1.47
|
|
10
|
Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice.
|
Gastroenterology
|
2012
|
1.44
|
|
11
|
Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas.
|
Haematologica
|
2013
|
1.17
|
|
12
|
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
|
Mol Cancer Ther
|
2013
|
1.13
|
|
13
|
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
|
Cancer Sci
|
2014
|
1.02
|
|
14
|
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
|
J Hematol Oncol
|
2014
|
0.99
|
|
15
|
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.
|
J Cancer
|
2013
|
0.94
|
|
16
|
Perceptions, practices, and consequences associated with foodborne pathogens and the feeding of raw meat to dogs.
|
Can Vet J
|
2009
|
0.92
|
|
17
|
KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
|
Cancer Chemother Pharmacol
|
2014
|
0.91
|
|
18
|
Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
|
Oncotarget
|
2014
|
0.90
|
|
19
|
Understanding XPO1 target networks using systems biology and mathematical modeling.
|
Curr Pharm Des
|
2014
|
0.86
|
|
20
|
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.
|
J Clin Psychopharmacol
|
2008
|
0.77
|
|
21
|
Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects.
|
J Clin Pharmacol
|
2007
|
0.75
|